Nicotinamide

Studied for: Cancer

Cancer

What the research found

Nicotinamide (a form of vitamin B3) has demonstrated strong evidence for reducing the risk of non-melanoma skin cancers (such as basal cell carcinoma and squamous cell carcinoma) and precancerous actinic keratoses.In the pivotal phase 3 ONTRAC trial of 386 immunocompetent high-risk individuals, oral nicotinamide 500 mg twice daily for 12 months resulted in a 20% relative rate reduction in new BCCs (95% CI, -6% to 39%; P = 0.12), alongside a significant 23% reduction in overall keratinocyte cancers.

Dose used in studies

500 mg twice daily

Side effects reported

well tolerated, mild digestive symptoms

References

Chen2015, Ali2016

Not medical advice

Trials are run on specific people, for specific reasons, over a set period. Your medications, conditions and bloodwork can change what is safe for you. Ask a doctor or pharmacist before starting.